Krystal Applies for Phase 2 Clinical Trial Plan to Evaluate Camostat Efficacy in COVID-19 Patients
[Asia Economy Reporter Geum Bo-ryeong] Crystal announced on the 26th that it has applied to the Ministry of Food and Drug Safety for an IND (Investigational New Drug) plan for a Phase 2 clinical trial to evaluate the efficacy and safety of Camostat in COVID-19 patients confirmed to be infected with the SARS-CoV-2 virus.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- [Breaking] Samsung Electronics Union: "Mediation Ends Due to Management's Rejection... General Strike Tomorrow"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The clinical trial will involve 100 patients aged 18 or older with mild to moderate COVID-19, confirmed positive for SARS-CoV-2 infection by RT-PCR (Real-Time Reverse Transcription Polymerase Chain Reaction), who have exhibited at least one symptom or sign of COVID-19 within 48 hours. The trial period will be a total of 28 days, including 7 days of administration and observation.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
